Wedbush Expects Weaker Earnings for Foghorn Therapeutics

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Equities researchers at Wedbush reduced their Q2 2025 earnings per share (EPS) estimates for shares of Foghorn Therapeutics in a note issued to investors on Wednesday, May 14th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.31) per share for the quarter, down from their prior estimate of ($0.28). The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. Wedbush also issued estimates for Foghorn Therapeutics’ Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($1.06) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $1.10 EPS.

Several other analysts have also recently commented on FHTX. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Foghorn Therapeutics in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Foghorn Therapeutics in a research note on Wednesday, April 30th. Citizens Jmp assumed coverage on Foghorn Therapeutics in a research note on Wednesday, April 23rd. They set a “mkt outperform” rating and a $9.00 price target for the company. Citigroup assumed coverage on Foghorn Therapeutics in a research note on Wednesday, April 23rd. They set an “outperform” rating for the company. Finally, B. Riley assumed coverage on Foghorn Therapeutics in a research note on Thursday, January 30th. They set a “buy” rating and a $10.00 price target for the company. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Foghorn Therapeutics has a consensus rating of “Buy” and a consensus price target of $12.13.

Foghorn Therapeutics Price Performance

FHTX opened at $4.43 on Monday. Foghorn Therapeutics has a 12 month low of $2.94 and a 12 month high of $10.25. The stock has a market cap of $246.84 million, a P/E ratio of -2.31 and a beta of 3.13. The stock’s 50 day moving average price is $3.98 and its 200 day moving average price is $5.14.

Foghorn Therapeutics (NASDAQ:FHTX) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.30). The company had revenue of $5.95 million for the quarter, compared to analyst estimates of $4.96 million.

Institutional Investors Weigh In On Foghorn Therapeutics

Several large investors have recently modified their holdings of FHTX. Jacobs Levy Equity Management Inc. boosted its position in shares of Foghorn Therapeutics by 8.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 241,816 shares of the company’s stock worth $883,000 after buying an additional 18,036 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Foghorn Therapeutics in the first quarter worth $68,000. DAFNA Capital Management LLC boosted its position in shares of Foghorn Therapeutics by 63.2% in the first quarter. DAFNA Capital Management LLC now owns 304,752 shares of the company’s stock worth $1,112,000 after buying an additional 118,035 shares during the period. Wellington Management Group LLP boosted its position in shares of Foghorn Therapeutics by 18.2% in the first quarter. Wellington Management Group LLP now owns 102,888 shares of the company’s stock worth $376,000 after buying an additional 15,819 shares during the period. Finally, Raymond James Financial Inc. boosted its position in shares of Foghorn Therapeutics by 9.3% in the first quarter. Raymond James Financial Inc. now owns 2,218,352 shares of the company’s stock worth $8,097,000 after buying an additional 188,969 shares during the period. 61.55% of the stock is owned by institutional investors.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.